Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.

Informacje na temat projektu

WoundRinse

Identyfikator umowy o grant: 816119

DOI

10.3030/816119

Projekt został zamknięty

Data podpisania przez KE 9 Maja 2018

Data rozpoczęcia 1 Czerwca 2018

Data zakończenia 30 Listopada 2018

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

SOFTOX SOLUTIONS AS
Norway

Periodic Reporting for period 1 - WoundRinse (Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.)

Okres sprawozdawczy: 2018-06-01 do 2018-11-30

Podsumowanie kontekstu i ogólnych celów projektu

SoftOx Solutions AS is in the process of developing an antimicrobial solution for treatment of infection on tissue. With the solution’s unique effect, the company aims to replace the use of antibiotics with the use of the Company’s topical applications. SoftOx’ antimicrobial solutions are efficient towards biofilm embedded and planktonic bacteria, virus, spores and fungi. The antimicrobial solution has been tested for potential resistance-issues, and it has not been observed inducement of resistance. The company’s first product line includes both medical devices and drugs, fighting chronic and antimicrobial resistant infections in acute and chronic wounds.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

Biocompatibility tests according to ISO guidelines, including relevant animal models, show that SoftOx antimicrobials are well tolerated and do not impede natural wound healing. Also, an animal study on horse legs showed significant reduction in bacterial burden, thus documenting effect in vivo. Hygiene hand-rub test of studies of 18 healthy volunteers’ (EN 1500) showed a Log 4 reduction of the E coli bacteria within 1 minute, demonstrating significant effect as a hand-disinfectant.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

The challenges targeted are some of the major issues for modern medicine, namely antibiotic resistance, biofilm infections in chronic wounds and hospital acquired infections. The O’Neill Report estimates a cost of up to USD 100 trillion and 10 million deaths yearly if there is no new alternative to the present antibiotic within 2050. Chronic wounds with biofilm infections are estimated to affect as much as 40 million patients yearly (leading to two million amputations) worldwide with a treatment cost of USD 260 billion.
Hospital acquired infections affects between 7 - 12 percent of hospitalized patients and have become a major source for spreading antibiotic-resistant bacteria. Products derived from the SoftOx technology has proven during the project to have the potential to become effective tools to help combat several of these challenges and threats to human health.

Company Logo